# Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

> **NCT05077969** · PHASE2 · TERMINATED · sponsor: **Leidos Life Sciences** · enrollment: 4 (actual)

## Conditions studied

- 2019 Novel Coronavirus Disease
- 2019 Novel Coronavirus Infection
- 2019-nCoV Disease
- 2019-nCoV Infection
- COVID-19
- COVID-19 Pandemic
- COVID-19 Virus Disease
- COVID-19 Virus Infection
- Covid19
- Coronavirus Disease 2019
- SARS-CoV2 Infection
- SARS-CoV-2 Acute Respiratory Disease

## Interventions

- **DRUG:** Famotidine
- **DRUG:** Celecoxib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05077969
- **Lead sponsor:** Leidos Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-29
- **Primary completion:** 2022-06-28
- **Final completion:** 2022-07-08
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Low recruitment
- **Last updated:** 2024-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05077969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05077969, "Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05077969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*